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Context: The pituitary-secreted nonapeptide arginine-vasopressin (AVP) is unstable and therefore
unsuited for diagnostic use, but its secretion can be estimated by measuring copeptin, the C-
terminal portion of the AVP precursor (pro-AVP).
Objective:Our objective was to investigate perinatal factors affecting copeptin concentrations in
infants at birth and at 3 d of life.
Design and Setting: We conducted a prospective cross-sectional study at a tertiary university
hospital.
Patients: Copeptin plasma concentrations were evaluated in 177 infants at birth, including 117
paired arterial/venous umbilical cord and 102 venous blood samples obtained at 3 d of life.
Main Outcome Measure: Copeptin concentrations were determined by a C-terminal pro-AVP
luminescence immunoassay.
Results: Arterial umbilical cord copeptin concentrations were consistently higher than matched
venous ones (median 18 vs. 10 pmol/liter, P  0.001), but both values were closely related (Rs 
0.825; P  0.001), and both were negatively related to arterial umbilical cord pH (Rs arterial/
venous  0.578/0.639; P  0.001). Although exceedingly high copeptin concentrations were
observed after vaginal birth in umbilical cord arterial [median (5–95% range)  1610 (85–5000)
pmol/liter] and venous [793 (6–4836) pmol/liter] plasma, copeptin concentrations were low after
primary cesarean section [arterial/venous 8 (3–907)/5 (5–504) pmol/liter]. Postnatal body weight
loss was associated with increased copeptin concentrations at d 3 (Rs 0.438; P 0.001) and was
inversely related to copeptin concentrations at birth (Rs  0.289 and 0.309; both P  0.001).
Conclusion: Vaginal birth is associated with a large release of copeptin that exceeds all values
published so far, including those in critically ill adult patients with shock or brain injury. Thus,
vaginal birth is arguably the most intense stressor in life. (J Clin Endocrinol Metab 95: 5091–5096,
2010)
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Crucial integration of a variety of neural and endocrineevents is a prerequisite for the successful adaptation
to extrauterine life. Parturition evokes a dramatic surge in
stress hormones facilitating the transition of the newborn
to air breathing, cardiovascular adaptation, thermogene-
sis, and glucose and water homeostasis.
The nonapeptide arginine-vasopressin (AVP), also
known as antidiuretic hormone, is one of these stress hor-
mones. AVP was first reported to be increased in cord
blood more than 30 yr ago (1, 2). However, the measure-
ment of AVP levels is laborious and for clinical use un-
suited because of its instability and short half-life. AVP
derives from a larger precursor peptide (provasopressin)
together with two other peptides, neurophysin II and
copeptin. Copeptin is released in an equimolar ratio to
AVP, circulates in plasma without physiological activity,
is highly stable especially after Ca2 chelation by EDTA,
and easy to measure (3).
This study aimed to evaluate copeptin concentrations
in paired samples of arterial and venous cord blood of
newborn infants as well as in venous blood collected 3 d
after birth.
Subjects and Methods
The study was carried out between July and September 2009.
After obtaining written informed consent, pregnant women pre-
senting for delivery at the University Hospital Zurich, Switzer-
land,were included. The studywas approved by the institutional
review board.
Of the 177 infants studied, 141 (80%) were term (37–41
completedweeks of gestational age), 21were near term (35or 36
wk), and 15 had a gestational age of 32–34 wk. Twenty-four
(13.6%) infants were twins, and three (1.7%) triplets. Sixty-two
of the 177 infants were delivered vaginally (35%), including 17
(9.6%) requiring instrumental support; 115 (65%) were deliv-
ered by cesarean section, including 40 cases of secondary cesar-
ean sectiondue toacute fetal ormaternaldistress.Thepercentage
of deliveries by cesarean section was significantly higher in pre-
term infants (31 of 36, 86%) than in term infants (83 of 141,
59%, P  0.003).
Blood samples were drawn from 143 umbilical veins at the
time of delivery with an additional 117 paired samples from
umbilical artery and an additional 68 paired samples from ve-
nous blood at postnatal d 3. Auxiliary blood samples were taken
at postnatal d 3 from 34 children.
Details of pregnancy (presence or absence of preeclampsia,
diabetes, infection, preterm labor, or administration of beta-
methasone for fetal lung maturation), delivery (umbilical artery
pH, base deficit, and hematocrit and amount of maternal blood
loss), and the infants’ birth characteristics (gestational age, birth
weight, and Apgar scores at 5 and 10 min) were collected from
the charts. The data on infants’ health after birth, whether the
infants were exclusively breastfed, additionally fed with for-
mula, or given iv fluid, and the daily weight control were
recorded by the staff on the maternity or neonatology ward,
respectively. Characteristics of mothers and infants are summa-
rized in Table 1.
Blood samples were collected immediately after birth by
puncture of the umbilical cord artery and vein and at 72 h (8
h, postnatal d 3) after birth by puncture of a vein from the back
of the hand. After collecting blood in EDTA tubes, samples were
stored at 4 C not exceeding 4 h until centrifugation was per-
formed, and plasma was transferred in a new EDTA tube and
subsequently frozen at28C.Measurementwasdone in a single
batch with a research sandwich immunoluminometric assay
(B  R  A  H M  S C-terminal pro-AVP luminescence immu-
noassay; B  R  A  H M  SAG,Hennigsdorf, Germany) as de-
scribed elsewhere (3), except that the capture antibody was re-
placed by amurinemonoclonal antibody directed to amino acids
137-144 (GRAGAL) of pro-AVP.
Statistical analyses were made using PASW version 18.0
(SPSS Inc., Chicago, IL) with strictly nonparametric tests (Spear-
man’s rank order correlation, Mann-Whitney U test, Kruskal-
Wallis, or Fisher’s exact test).
TABLE 1. Selected characteristics of mothers and their infants
Characteristics
Venous plasma, umbilical cord
(n  143)
Arterial plasma, umbilical cord
(n  117)
Venous plasma, d 3
(n  102)
Infant sex
Male 78 (55) 69 (59) 60 (59)
Infant birth weight (g)
2000 11 (8) 6 (5) 8 (8)
2000–3000 47 (32) 38 (31) 26 (26)
3001–4000 77 (54) 66 (56) 61 (61)
4000 8 (6) 7 (6) 7 (7)
Infant gestational age at birth
(completed weeks)
Preterm 32–37 32 (22) 26 (22) 20 (20)
Term 37–41 111 (78) 91 (78) 82 (80)
Mode of delivery
Cesarean section primary 74 (52) 63 (54) 42 (42)
Cesarean section secondary 26 (18) 23 (20) 21 (21)
Spontaneous vaginal 30 (21) 23 (20) 28 (28)
Instrumental vaginal 13 (9) 8 (7) 11 (11)
Results are shown as n (%).
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Results
Paired umbilical cord arterial and venous plasma copeptin
concentrations were closely related (n 117; Rs 0.825;
P  0.001). Copeptin concentrations were consistently
higher in arterial than in venous samples (median18 vs.10
pmol/liter, P  0.001). Copeptin concentrations mea-
sured at 3 d of life [n  102; M (5–95% range)  14.0
(5.5–56.6) pmol/liter] were significantly (P  0.001)
lower than copeptin concentrations in either umbilical
cord arterial or venous plasma. There was not a correla-
tion of copeptin concentrations in paired samples of ar-
terial umbilical cord plasma and d 3 venous plasma (n 
54; Rs  0.061; P  0.664) or in paired samples of
venous umbilical cord plasma and d 3 venous plasma (n
68; Rs  0.133; P  0.281).
Analyzing copeptin concentrations in respect to clinical
dates revealed a significant (P0.001) inverse correlation
of copeptin concentrations in both arterial umbilical cord
plasma and venous umbilical cord plasma with umbilical
artery pH (Rs  0.639 and 0.578, respectively) and
umbilical artery base excess (Rs  0.645 and 0.638,
respectively), as shown in Fig. 1. Apgar scores at 5 and 10
min of life and hematocrit in umbilical cord blood as well
as mothers’ blood loss during delivery did not correlate
with copeptin concentrations in any plasma samples, nei-
ther arterial and venous umbilical cord plasmanor plasma
samples drawn at d 3.
The mode of delivery affected copeptin concentrations
in arterial and venous umbilical cord plasma very strongly
(both P 0.001) (see Fig. 1) but had no impact on copep-
tin concentrations in d 3 venous plasma. The distributions
of copeptin concentrations in arterial and venous umbil-
ical cordplasmawith respect to the variousdeliverymodes
are summarized in Table 2.
Gestational age was found to be directly related with
copeptin concentrations in arterial and venous umbilical
cordplasma (Rs0.377and0.416, respectively; bothP
0.001) but not with copeptin concentrations in d 3 venous
plasma. However, birth weight depicted only a weak cor-
relation to copeptin concentrations in venous umbilical
cord plasma (Rs 0.183; P 0.029) but not with copep-
tin concentrations in either arterial umbilical cord plasma
or d 3 venous plasma. This finding of lower copeptin con-
centrations in umbilical cord blood of infants born pre-
termorwith lowbirthweightwasmainly attributed to the
fact that the percentage of deliveries by cesarean section
was significantly higher inpreterm infants (31of 36, 86%)
than in term infants (83 of 141, 59%, P  0.003).
The maximal weight loss in postnatal adaptation oc-
curred between d 2 and 5, on average at d 3. Intravenous
fluid was administered in eight infants, all of whom
weighed less than 1800 g at birth and therefore received iv
fluid following institutional guidelines. Only 40 infants of
the study population were exclusively breastfed, 62 re-
ceived some additional hydrolyzed starch solution, and67
received formula milk with or without mother’s milk.
There was an inverse relation betweenmaximal weight
loss and copeptin concentrations in arterial as well as in
venous umbilical cord plasma (Rs0.309 and0.289,
respectively; both P  0.001), indicating increased post-
natal weight loss in infants with low copeptin concentra-
tions at birth. Thenwe compared copeptin concentrations
in venous umbilical cord plasma in all infants subdivided
in groups with mild (2–5%, n  33), moderate (6–7%,
n 51), and severe maximal (8–12%, n 53) postnatal
weight loss. Copeptin concentrations at birth were signif-
icantly higher in infants with mild compared with mod-
erate or severe maximal postnatal weight loss (P 0.017
and P  0.0001, respectively; Fig. 2A).
Maximal weight loss correlated directly with copeptin
concentrations in venous plasma drawn at 3 d of life (Rs
0.438; P  0.001) but not with sodium concentrations,
hematocrit, or bilirubin at d 3. All infants with copeptin
values from d 3 were subdivided in groups with mild
(n  29), moderate (n  36), and severe maximal (n 
37) postnatal weight loss. Copeptin concentrations at d
3 were significantly higher in infants belonging to the
group with severe compared with mild or moderate
maximal weight loss (P  0.0001 and P  0.011, re-
spectively; Fig. 2B).
There was not a relation between maximal weight loss
and gestational age at birth or between maximal weight
loss and birth weight.
FIG. 1. Association of copeptin concentrations with pH in arterial
umbilical cord samples. Data points are represented according to the
delivery mode: , vaginal spontaneous; f, instrumental; ‚, cesarean
primary; E cesarean secondary.
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Discussion
Until now, copeptinhadbeen studied exclusively inadults.
These studieswere donewith respect to changes in plasma
osmolality, in settings of mild to life-threatening physical
stress, and in various diseases. Normal copeptin concen-
trations in healthy adults were consistently reported to be
about 5 pmol/liter, as reviewed byMorgenthaler et al. (4).
Water deprivation has been shown to increase copeptin
concentrations 4-fold [M 19.9 ( SD 4.8) pmol/liter] (5),
and severe stress, e.g. extubation of surgical patients, was
found to result in a 10-fold increase [M67.5 (interquartile
range 37.8–110) pmol/liter] (6). The most pronounced
surges in copeptin hitherto described were in patients suf-
fering from shock, either septic [M 375 (range 59–1572)
pmol/liter] (7) or hemorrhagic [M 269 (range 241–456)
pmol/liter] (8). These 20-fold increased copeptin concen-
trations in adults suffering from life-threatening events are
still far below the copeptin concentrationswemeasured in
healthy, naturally delivered infants. Determination of
copeptin concentrations in all these studies investigating
adults was performed by the same C-terminal pro-AVP
luminescence immunoassay as applied here, allowing for
a direct comparison. Thus, vaginal delivery provokes a
unique surge in copeptin plasma concentration (Fig. 1)
incommensurable with all reported changes in copeptin
concentrations in adult patients.
Hypoxia has been described to augment a strong AVP
release within a short time in various animal models (9–
13), and similarly, perinatal asphyxia in humans has been
found to trigger a decisive AVP response (14, 15). Because
also normal vaginal delivery in humans has been shown to
trigger AVP release (1, 2), some investigators have come
up with the hypothesis that fetal AVP release may effec-
tively reduce placental blood flow during uterine contrac-
tion. This could contribute to acute fetal stress and hypoxia
even during normal labor (16–18). However, our finding
that copeptin concentrations in umbilical cord plasma are
orders ofmagnitude (on average 500 times) higher in infants
deliveredvaginallycomparedwiththosedeliveredbyelective
cesareansection indicate thatvaginalbirth is the largest stres-
sor for the body found so far, e.g. larger than brain trauma,
ischemic stroke, or severe shock in
adults (7, 8, 19, 20).
Copeptin concentrations in arterial
umbilical cord plasma were found to
be on average 1.8-fold above those in
paired venous umbilical cord plasma
samples. Because copeptin appears to
be too large (39-amino-acid glyco-
peptide) to cross the placental bar-
rier, this observation leads to two hy-
potheses. First, measured copeptin
levels in cordbloodareof fetal origin,
and second, some circulating copep-
tin is captured during the placental
passage. Copeptin is thought to be
without physiological function, and
therefore, the placental clearance is
somewhat surprising.
In our study, most newborns were
bornat term,but36 (20%)wereborn
between 32 and 36 completed weeks
of gestation. Although there was a
FIG. 2. A, Correlation of copeptin in venous umbilical cord plasma with maximal postnatal
weight loss. Maximal postnatal weight loss is grouped in mild (2–5%, n  33), moderate
(6–7%, n  51), and strong (8–12%, n  53) loss. Data are presented as box (interquartile
range) and whisker (5–95% range) plots. Significant statistical differences were noted between
the following groups: mild vs. moderate (P  0.017) and mild vs. strong (P  0.0001). No
significant difference was noted between moderate vs. strong (P  0.27). B, Correlation of
copeptin in venous plasma at d 3 with maximal postnatal weight loss. Maximal postnatal weight
loss is grouped in mild (2–5%, n  29), moderate (6–7%, n  36), and strong (8–12%, n 
37) loss. Data are presented as box (interquartile range) and whisker (5–95% range) plots.
Significant statistical differences were noted between the following groups: mild vs. moderate
(P  0.011) and mild vs. strong (P  0.0001). No significant difference was noted between
moderate vs. severe (P  0.054).
TABLE 2. Copeptin intervals in arterial and venous umbilical cord plasma
Mode of delivery n
Median copeptin
(pmol/liter)
95% reference interval
(pmol/liter) Pa
Cesarean primary 63/73 8/5 3–907/5–504
Cesarean secondary 23/27 14/11 4–2240/2–2260 0.01/0.01
Vaginal spontaneous 23/30 1610/634 82–5000/6–5000 0.001/0.001
Vaginal instrumental 8/13 1786/1324 1786–5000/90–4900 0.001/0.001
Results are shown as arterial/venous.
a Significance between cesarean primary and with each other mode of delivery.
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significant positive and moderate correlation of copeptin
levels in arterial and venous cord blood with gestational
age, there was no consistent relationship with birth
weight. A closer view on this finding reveals that the high
percentage of cesarean sections within the group of pre-
term infants (86%) accounted for their overall low copep-
tin levels. After adjusting for vaginal delivery and second-
ary cesarean section, the difference between term and
preterm infants disappeared. This is in line with previous
findings investigating AVP (16, 21). One important lim-
itation of our analysis is the small group of premature
infants included, and there were no infants under 32 wk
gestational age, which represent the most vulnerable
group of patients in neonatal intensive care units.
AVPorchestrates amagnitude of actions coveringwell-
understood mechanisms including water retention and
maintenance of blood pressure but also recently discov-
ered roles in social behavior (22). Thus, it is intriguing to
assume that AVP is involved in postnatal physical and
behavioral adaptation (e.g. bonding). Reports linking el-
evated AVP at birth with delayed voiding (23, 24) are in
support of the inverse relation of high copeptin in umbil-
ical cord blood andminor postnatal weight loss we found
in this study (Fig. 2A). This may offer an explanation why
infants born by cesarean section are prone to dehydration
more frequently then infants delivered vaginally (25). In-
creased rates of breathingdisorders after cesareandelivery
are common (26, 27), and it is tempting to speculate that
low AVP after cesarean delivery is involved in compro-
mised postnatal pulmonary adaptation. In contrast to pe-
ripheral vasculature, AVP leads to vasodilatation of pul-
monary vasculature under hypoxic conditions through
AVP receptor-mediated endothelial release of NO (28,
29). In addition, type II pneumocytes express AVP recep-
tors and have been shown to secrete surfactant when ex-
posed to AVP (30, 31). Thus, physiological hypoxia dur-
ingvaginalbirth causinga robustAVPreleasemayprepare
infants for successful postnatal adaptation, whereas in-
fants delivered by primary cesarean section (that is before
the onset of labor) have no relevant AVP release and are
thus lesswell prepared to resume respiratory oxygenation.
Even exceedingly high copeptin concentrations at birth
returned to near-normal values at d 3 of life; there was no
correlation between concentrations at both time points.
This is in agreement with data fromAVP analyses (16, 21,
32, 33) and from copeptin analyses in adults with acute
myocardial infarction (34). Already 24 h after pain onset,
copeptin concentrations normalized in themajority of pa-
tients. Moreover, the inverse correlation of copeptin con-
centrations at d 3 and dehydration as indicated by the
infants’ weight loss implicates an intact osmotic AVP reg-
ulation (Fig. 2B). Copeptin concentrations at d 3 were in
about the same range as documented for adults during
adaptation to dehydration (5). Thus, we conclude that
after releasing AVP at birth, there are neither unusual low
copeptin concentrations afterward nor a hampered os-
motic AVP regulation.
Although an increased AVP secretion at the time of
birth appears to be beneficial with respect to lung function
and water retention, the magnitude of the surge after nor-
mal vaginal delivery is surprising. Several hypotheses may
be invoked. First, newborns might require disproportion-
ately high AVP concentrations because of low receptor
expression or receptor affinity in target tissues. Second,
AVP has a pivotal role in adaptation after birth, warrant-
ing the effort. Third, AVP is released in high concentra-
tions for binding to AVP receptor-expressing neurons, pi-
tuitary gland cells involved in ACTH release, and for
oxytocin receptor activation linked tobonding (22).There
is indeed a fast-growing wealth of data uncovering evo-
lutionary conserved functionof vasopressin inmodulating
complex social behavior and cognition.
Recent data have revealed copeptin as a novel, inde-
pendent prognosticmarker in adult patientswith ischemic
stroke (20) and with severe injury after brain trauma in
adults (19). In these settings, copeptin was shown to be
superior to various markers such as protein S-100B and
neuron-specific enolase in predicting severity level and
outcome (20). Severe perinatal asphyxia damages brain in
a manner similar to ischemic stroke resulting in hypoxic-
ischemic encephalopathy, and neonatologists are looking
for novel independent prognosticmarkers to guide clinical
decision making with respect to applying therapeutic hy-
pothermia and counseling parents. Further studies may
explore whether extremely high copeptin concentrations
at birthorkinetic changes of copeptin concentrations after
birth may herald poor outcome.
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